



Marie Curie  
Actions

IT-DED<sup>3</sup>



# Development of new carriers to improve the bioavailability of natural compounds to treat ocular surface disorders

Luna Krstić (ESR6)


Joint meeting OcuTher and IT-DED<sup>3</sup>  
Nice, October 16, 2019




Universidad de Valladolid



# WP2-Preclinical Drug Development




# Ocular surface as a target



- ✓ Excellent Accessibility
- ✓ Drug Delivered Locally
- ✓ Effects Observed Easily
- ✗ Physiological Processes
- ✗ Frequent Administration
- ✗ Low Bioavailability


# The potential of natural occurring compounds

ANTIOXIDANT



POLYPHENOLS

ANTI-INFLAMMATORY



ANTIBACTERIAL






ANTIVIRAL



Universidad de Valladolid

**25** ioba  
Instituto Universitario de  
Oftalmobiología Aplicada  
1994 - 2019  
"25 años investigando para curar mejor"

# Types of carriers employed




Stability Profile

Solubility

Bioavailability

- Physicochemical Characterization
- *In Vitro & In Vivo* Tests



# Thank you for your attention!